DexCom Stock Drops After Q3 Results, Announces C-Suite Transition
DexCom Stock Drops After Q3 Results, Announces C-Suite Transition
Dexcom's third-quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year," said Sayer. "We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025."DexCom, Inc. (NASDAQ:DXCM) reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report.
德康医疗公司（NASDAQ:DXCM）在周四收盘后发布了其第三季度业绩报告。以下是报告中的详细信息。
The Details: DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
详细信息：DexCom报告每股45美分的季度收益，超过了43美分的分析师共识估计。季度营业收入为99420万美元，超过了99071万美元的分析师共识估计，并较去年同期的97500万美元销售额有所增加。
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
DexCom还宣布，首席商业官兼执行副总裁Teri Lawver将于年底退休。Lawver将继续担任Dexcom的特别顾问，直到2025年初，董事长、总裁兼首席执行官Kevin Sayer将在公司为新的首席商业官进行全球搜寻的同时，负责领导商业机构。
Dexcom's third-quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year," said Sayer. "We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025."
Sayer表示：“德康医疗公司第三季度的业绩符合我们的预期，我们的团队迅速响应了今年年初出现的业务动态。” “我们在季度内取得了显著进展，推动了执行能力的提升，使公司能够按计划继续势头，进入2025年。”
Outlook: DexCom affirmed its fiscal 2024 sales outlook of between $4 billion and $4.05 billion.
展望：DexCom确认其2024财年销售预期在40亿美元至40.5亿美元之间。
DXCM Price Action: According to Benzinga Pro, DexCom shares are down 7.94% after-hours at $68.91 at the time of publication Thursday.
DXCM价格走势：根据Benzinga Pro的数据，德康医疗公司股价在发布时为每股68.91美元，盘后下跌了7.94%。
Read Also:
阅读更多:
- Bank Of America CEO Cautions Fed Not To 'Go Too Fast Or Too Slow' On Interest Rate Cuts
- 美国银行首席执行官警告联邦储备委员会在利率削减方面‘不要走得太快或太慢’。
Photo: Shutterstock
图片：shutterstock
